Hepatitis aguda por ticlopidina. Presentación de 12 casos y revisión de la literatura

• DOI: 10.33588/rn.3311.2001285
• Publication Date: 2019-02-15T07:47:11Z
• Authors: Ángeles E. Pizarr...; Raúl J. Andrade B...; Miren García Cortés; María Isabel Luce...; José Manuel Pérez...; Manuel Puertas Mo...; Herminia Sánchez ...; José Luis Montero...; José Antonio Durá...; Manuel Jiménez Saenz; Antonio Ruiz Montero; María José Soto C...; Luis Rodrigo Saez; Ruth de Francisco...; Ramiro Alcántara ...; Raquel Camargo Ca...
• Keywords: Ticlopidine; Hepatitis C

To analyze the characteristics of hepatotoxicity due to ticlopidine.We describe all case attributed ticlopidine and reported Register drug associated hepatopathies. We also obtained data from MEDLINE Spanish Medical Index regarding cases during period 1982 2001.We twelve hepatopathy related use ticlopidine. These made up 5% notified Register. Eighty three percent patients were male, an average age 68 years. Sixty six required hospital admission. The latent varied between 2 13 weeks. liver lesion was cholestatic type in 75% cases, hepatocellular 16.6% mixed 8.3%. Twenty five had received sub therapeutic doses.Ticlopidine is often hepatotoxicity. This seems be idiosyncratic mechanism mainly cholestatic. lower dosage than that recommended means desired effect not attained but does protect against development Doctors who this should aware so as establish true risk benefit relation.